Health Stocks in Motion
Updated from 2:15 p.m. EDT
Shares of eResearch Technology (ERES) were among the worst-performing health and pharmaceutical stocks Thursday, falling 16.4% after the company posted third-quarter earnings that fell below Wall Street expectations and warned that fourth-quarter earnings and sales would be below expectations as well.
The supplier of technology used by biotech companies earned 13 cents a share during the third quarter on sales of $28 million. Analysts polled by Thomson First Call were expecting earnings of 14 cents a share on sales of $27.3 million. Looking ahead, eResearch forecast a fourth-quarter profit of 11 cents to 15 cents a share on sales of $26 million to $30 million. Analysts had been expecting earnings of 16 cents a share on sales of $31.5 million. Shares traded down $2.23 to $11.36.
Align Technology (ALGN) fell 33.2% after the company delivered in-line third-quarter earnings results but turned in weaker-than-expected sales results. The maker of teeth-straightening products posted pro forma earnings of 7 cents a share on sales of $45.8 million. Analysts were expecting earnings of 7 cents a share on sales of $47.3 million. A year ago, Align earned 2 cents a share on sales of $34 million. Shares of Align traded down $4.92 to $9.90.Shares of Apria Healthcare (AHG) fell 4.3% after the company posted mixed third-quarter financial results and lowered its full-year earnings growth projections. The home health care company earned 60 cents a share during the third quarter on sales of $364.6 million. Analysts were expecting earnings of 59 cents a share on sales of $366.5 million. Looking ahead, Apria said that it believes it will turn in full-year earnings growth of 6% to 8%. Previously, the company said that it would grow earnings by 7% to 9%. Shares traded down $1.25 to $27.90.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV